Journal of Neuro-Oncology

, 105:119 | Cite as

Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG

  • Ute Bartels
  • Cynthia Hawkins
  • Gilbert Vézina
  • Larry Kun
  • Mark Souweidane
  • Eric Bouffet
Meeting Proceedings

Abstract

Diffuse intrinsic pontine glioma (DIPG) nearly exclusively affects children. The prognosis of DIPGs has remained grim despite more than three decades of clinical research and numerous clinical trials. More than 90% of the children with DIPG will succumb within 2 years of diagnosis. The tumor’s incidence is still undefined, but data suggest 100–150 affected children annually in the US. The single proven effective treatment modality in DIPG remains radiation therapy. For the majority of patients however this treatment is only of transient effectiveness. Recent breakthroughs in the understanding of the molecular biology of DIPG have raised new hope and opened new avenues for therapeutic options. The advancement of basic and translational research and cooperation was the objective of the Toronto Think Tank, as new approaches are urgently needed.

Keywords

Diffuse intrinsic pontine glioma DIPG Think tank 

References

  1. 1.
    Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248PubMedCrossRefGoogle Scholar
  2. 2.
    Smith MA, Freidlin B, Ries LA, Simon R (1998) Trends in reported incidence of primary malignant brain tumors in children in the United States. J Natl Cancer Inst 90(17):1269–1277PubMedCrossRefGoogle Scholar
  3. 3.
    Bouchard J (1966) Radiation therapy of tumors and diseases of the nervous system. Lea & Febiger, PhiladelphiaGoogle Scholar
  4. 4.
    Barkovich AJ (1990) Pediatric neuroimaging. Raven Press, New YorkGoogle Scholar
  5. 5.
    Edwards MS, Wara WM, Urtasun RC, Prados M, Levin VA, Fulton D, Wilson CB, Hannigan J, Silver P (1989) Hyperfractionated radiation therapy for brain-stem glioma: a phase I–II trial. J Neurosurg 70:691–700PubMedCrossRefGoogle Scholar
  6. 6.
    Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE (1996) Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The pediatric Oncology Group. Cancer 77:555–562PubMedCrossRefGoogle Scholar
  7. 7.
    Freeman CR, Krischer J, Sanford RA, Cohen ME, Burger PC, Kun L, Halperin EC, Crocker I, Wharam M (1991) Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. Cancer 68(3):474–481PubMedCrossRefGoogle Scholar
  8. 8.
    Janssens GO, Gidding CE, Van Lindert EJ, Oldenburger FR, Erasmus CE, Schouten-Meeteren AY, Kaanders JH (2009) The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study. Int J Radiat Oncol Biol Phys 73:722–726PubMedCrossRefGoogle Scholar
  9. 9.
    Lewis J, Lucraft H, Gholkar A (1997) UKCCSG study of accelerated radiotherapy for pediatric brain stem gliomas United Kingdom Childhood Cancer Study Group. Int J Radiat Oncol Biol Phys 38:925–929PubMedCrossRefGoogle Scholar
  10. 10.
    Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group Phase III trial comparing conventional vs hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43:959–964PubMedCrossRefGoogle Scholar
  11. 11.
    Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB, Selch MT, Cherlow JM, Finlay JL, Wara WM (1994) Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 74:1827–1834PubMedCrossRefGoogle Scholar
  12. 12.
    Packer RJ, Littman PA, Sposto RM, D’Angio G, Priest JR, Heideman RL, Bruce DA, Nelson DF (1987) Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas. Int J Radiat Oncol Biol Phys 13:1647–1651PubMedCrossRefGoogle Scholar
  13. 13.
    Chuba PJ, Zamarano L, Hamre M, Bhambhani K, Canady A, Guys MB, Matter A, Portillo G, Chung-bin S, Fontanesi J (1998) Permanent I-125 brain stem implants in children. Childs Nerv Syst 14:570–577PubMedCrossRefGoogle Scholar
  14. 14.
    Combs SE, Steck I, Schulz-Ertner D, Welzel T, Kulozik AE, Behnisch W, Huber PE, Debus J (2009) Long-term outcome of high-precision radiotherapy in patients with brain stem gliomas: results from a difficult-to-treat patient population using fractionated stereotactic radiotherapy. Radiother Oncol 91:60–66PubMedCrossRefGoogle Scholar
  15. 15.
    Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U (2008) Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 51:110–117PubMedCrossRefGoogle Scholar
  16. 16.
    Mundinger F, Braus DF, Krauss JK, Birg W (1991) Long-term outcome of 89 low-grade brain-stem gliomas after interstitial radiation therapy. J Neurosurg 75:740–746PubMedCrossRefGoogle Scholar
  17. 17.
    Schulz-Ertner D, Debus J, Lohr F, Frank C, Hoss A, Wannenmacher M (2000) Fractionated stereotactic conformal radiation therapy of brain stem gliomas: outcome and prognostic factors. Radiother Oncol 57:215–223PubMedCrossRefGoogle Scholar
  18. 18.
    Bernier-Chastagner V, Grill J, Doz F, Bracard S, Gentet JC, Marie-Cardine A, Luporsi E, Margueritte G, Lejars O, Laithier V, Mechinaud F, Millot F, Kalifa C, Chastagner P (2005) Topotecan as a radiosensitizer in the treatment of children with malignant diffuse brainstem gliomas: results of a French Society of Paediatric Oncology Phase II Study. Cancer 104:2792–2797PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 13:410–416PubMedCrossRefGoogle Scholar
  20. 20.
    Sirachainan N, Pakakasama S, Visudithbhan A, Chiamchanya S, Tuntiyatorn L, Dhanachai M, Laothamatas J, Hongeng S (2008) Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 10:577–582PubMedCrossRefGoogle Scholar
  21. 21.
    Mayo C, Yorke E, Merchant TE (2010) Radiation associated brainstem injury. Int J Radiat Oncol Biol Phys 76:S36–S41PubMedCrossRefGoogle Scholar
  22. 22.
    Freeman CR, Perilongo G (1999) Chemotherapy for brain stem gliomas. Childs Nerv Syst 15:545–553PubMedCrossRefGoogle Scholar
  23. 23.
    Frappaz D, Schell M, Thiesse P, Marec-Berard P, Mottolese C, Perol D, Bergeron C, Philip T, Ricci AC, Galand-Desme S, Szathmari A, Carrie C (2008) Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 10:599–607PubMedCrossRefGoogle Scholar
  24. 24.
    Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP (2003) A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro Oncol 5:8–13PubMedGoogle Scholar
  25. 25.
    Chastagner P, Bouffet E, Grill J, Kalifa C (2001) What have we learnt from previous phase II trials to help in the management of childhood brain tumours? Eur J Cancer 37:1981–1993PubMedCrossRefGoogle Scholar
  26. 26.
    Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A, Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P, Statkevich P, Marco A, Batra V, Dugan M, Pearson AD (1998) Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children’s Cancer Study Group. Br J Cancer 78:652–661PubMedCrossRefGoogle Scholar
  27. 27.
    Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D (2002) Temozolomide in malignant gliomas of childhood: a United Kingdom Children’s Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20:4684–4691PubMedCrossRefGoogle Scholar
  28. 28.
    Bouffet E, Raquin M, Doz F, Gentet JC, Rodary C, Demeocq F, Chastagner P, Lutz P, Hartmann O, Kalifa C (2000) Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88:685–692PubMedCrossRefGoogle Scholar
  29. 29.
    Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, Freeman C (2008) Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer 50:227–230PubMedCrossRefGoogle Scholar
  30. 30.
    Sharp JR, Bouffet E, Stempak D, Gammon J, Stephens D, Johnston DL, Eisenstat D, Hukin J, Samson Y, Bartels U, Tabori U, Huang A, Baruchel S (2010) A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer 46:3271–3279PubMedCrossRefGoogle Scholar
  31. 31.
    Wolff JE, Westphal S, Molenkamp G, Gnekow A, Warmuth-Metz M, Rating D, Kuehl J (2002) Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87:945–949PubMedCrossRefGoogle Scholar
  32. 32.
    Massimino M, Bode U, Biassoni V, Fleischhack G (2011) Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 11:247–256PubMedCrossRefGoogle Scholar
  33. 33.
    Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, Pai Panandiker AS, Leung W, Chin TK, Stewart CF, Kocak M, Rowland C, Merchant TE, Kaste SC, Gajjar A (2010) Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762–4768PubMedCrossRefGoogle Scholar
  34. 34.
    Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR (2011) A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium. Neuro Oncol 13:290–297PubMedCrossRefGoogle Scholar
  35. 35.
    Broniscer A, Baker JN, Baker SJ, Chi SN, Geyer JR, Morris EB, Gajjar A (2010) Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 116:4632–4637PubMedCrossRefGoogle Scholar
  36. 36.
    Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337–1344PubMedCrossRefGoogle Scholar
  37. 37.
    Angelini P, Hawkins C, Laperriere N, Bouffet E, Bartels U (2011) Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol 101:75–81PubMedCrossRefGoogle Scholar
  38. 38.
    Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC (2005) Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 23:6172–6180PubMedCrossRefGoogle Scholar
  39. 39.
    Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE (2007) Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol 25(21):3137–3143PubMedCrossRefGoogle Scholar
  40. 40.
    MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26:919–924PubMedCrossRefGoogle Scholar
  41. 41.
    Fouladi M, Laningham F, Wu J, O’Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806–4812PubMedCrossRefGoogle Scholar
  42. 42.
    Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T (2009) Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer 52:169–176PubMedCrossRefGoogle Scholar
  43. 43.
    Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF (2007) A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group study. Cancer 110:2535–2541PubMedCrossRefGoogle Scholar
  44. 44.
    Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM (2007) Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9:145–160PubMedCrossRefGoogle Scholar
  45. 45.
    Gururangan S, Turner CD, Stewart CF, O’Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE (2008) Phase I trial of VNP40101 M (Cloretazine) in children with recurrent brain tumors: a Pediatric Brain Tumor Consortium Study. Clin Cancer Res 14:1124–1130PubMedCrossRefGoogle Scholar
  46. 46.
    Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Meresse V, Vassal G (2011) Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 13:109–118PubMedCrossRefGoogle Scholar
  47. 47.
    Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28:3069–3075PubMedCrossRefGoogle Scholar
  48. 48.
    Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, Blaney SM, Packer RJ, Gururangan S, Banerjee A, Kieran MW, Kun LE, Gilbertson RJ, Boyett JM (2010) A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer 46:3287–3293PubMedCrossRefGoogle Scholar
  49. 49.
    Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, McKnight T, Poussaint TY, Broniscer A, Blaney SM, Boyett JM, Kun LE (2008) Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 10:341–347PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Ute Bartels
    • 1
  • Cynthia Hawkins
    • 2
  • Gilbert Vézina
    • 3
  • Larry Kun
    • 4
  • Mark Souweidane
    • 5
    • 6
  • Eric Bouffet
    • 1
  1. 1.Division of Haematology/OncologyThe Hospital for Sick Children, University of TorontoTorontoCanada
  2. 2.Division of PathologyThe Hospital for Sick Children, University of TorontoTorontoCanada
  3. 3.Department of Radiology and Diagnostic ImagingChildren’s National Medical CenterWashingtonUSA
  4. 4.Department of Radiological SciencesSt. Jude Children’s Research HospitalMemphisUSA
  5. 5.Department of Neurological SurgeryWeill Medical College of Cornell University and Memorial Sloan-Kettering Cancer CenterNew YorkUSA
  6. 6.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations